@article{369510ff49b3433eb0d09fe26beecb16,
title = "No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease",
abstract = "Parkinson's disease (PD) is a disorder with highly variable clinical phenotype. The identification of genetic variants modifying age at onset and other traits is of great interest because it may provide insight into disease mechanisms and potential therapeutic targets. A variant in the DNM3 gene (rs2421947) has been reported as a genetic modifier of age at onset in LRRK2-associated PD. To test the possible effect of genetic variation in DNM3 on age at onset in idiopathic PD, we examined rs2421947 in a total of 5918 patients with PD from seven data sets. We also assessed the potential effect of all common variants in the DNM3 locus. There was no significant association between rs2421947 and age at onset in any of the individual studies. Meta-analysis of the seven studies was nonsignificant and the between-study heterogeneity was minimal. No other common variants within the DNM3 locus affected age at onset. In conclusion, we find no evidence of an association between DNM3 variants and age at onset in idiopathic PD.",
keywords = "Age at onset, DNM3, Parkinson's disease",
author = "Victoria Berge-Seidl and Lasse Pihlstr{\o}m and Wszolek, {Zbigniew K.} and Ross, {Owen A.} and Mathias Toft",
note = "Funding Information: The authors thank all study participants, investigators, and funding partners for their contribution to the data analyzed in the current publication. The funding organizations had no role in study design, data collection and analysis, decision to publish, or preparation of the article. VBS and MT are funded by a grant from the South-Eastern Norway Regional Health Authority. MT is also supported by the Research Council of Norway. LP is supported by the Norwegian Health Association. Mayo Clinic is a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS P50 #NS072187 to OR and ZKW); ZKW is also funded by Mayo Clinic Center for Individualized Medicine, Mayo Clinic Neuroscience Focused Research Team (Cecilia and Dan Carmichael Family Foundation, and the James C. and Sarah K. Kennedy Fund for Neurodegenerative Disease Research at Mayo Clinic in Florida), the gift from Carl Edward Bolch, Jr, and Susan Bass Bolch, the Sol Goldman Charitable Trust, and Donald G. and Jodi P. Heeringa. OR is supported by NINDS R01 NS078086, Department of Defense award W81XWH-16-PRMRP-IIRA, Michael J. Fox Foundation. The analyses presented in the current publication are based on the use of study data downloaded from the dbGaP website, under dbGaP accession phs000126.v1.p1, phs000048.v1.p1, phs000089.v3.p2 and phs000196.v2.p1. Data were also obtained from the Parkinson's Progression Markers Initiative (PPMI) database ( www.ppmi-info.org/data ). For up-to-date information on the study, visit www.ppmi-info.org . PPMI—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners including AbbVie, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, Takeda, Teva and UCB. Funding Information: The authors thank all study participants, investigators, and funding partners for their contribution to the data analyzed in the current publication. The funding organizations had no role in study design, data collection and analysis, decision to publish, or preparation of the article. VBS and MT are funded by a grant from the South-Eastern Norway Regional Health Authority. MT is also supported by the Research Council of Norway. LP is supported by the Norwegian Health Association. Mayo Clinic is a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS P50 #NS072187 to OR and ZKW); ZKW is also funded by Mayo Clinic Center for Individualized Medicine, Mayo Clinic Neuroscience Focused Research Team (Cecilia and Dan Carmichael Family Foundation, and the James C. and Sarah K. Kennedy Fund for Neurodegenerative Disease Research at Mayo Clinic in Florida), the gift from Carl Edward Bolch, Jr, and Susan Bass Bolch, the Sol Goldman Charitable Trust, and Donald G. and Jodi P. Heeringa. OR is supported by NINDS R01 NS078086, Department of Defense award W81XWH-16-PRMRP-IIRA, Michael J. Fox Foundation. The analyses presented in the current publication are based on the use of study data downloaded from the dbGaP website, under dbGaP accession phs000126.v1.p1, phs000048.v1.p1, phs000089.v3.p2 and phs000196.v2.p1. Data were also obtained from the Parkinson's Progression Markers Initiative (PPMI) database (, www.ppmi-info.org/data). For up-to-date information on the study, visit, www.ppmi-info.org. PPMI?a public-private partnership?is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners including AbbVie, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, Takeda, Teva and UCB. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",
year = "2019",
month = feb,
doi = "10.1016/j.neurobiolaging.2018.09.022",
language = "English (US)",
volume = "74",
pages = "236.e1--236.e5",
journal = "Neurobiology of aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
}